Venmax Drugs and Pharmaceuticals Ltd
Ticker: VENMAX
Decent
68/100
☆ Add to Watchlist
Investing Reference
Price
23.08
Market Cap
16.83
Debt/Equity
0.0113
ROE %
-0.532
PB
3.8173
Promoter %
23.135
Pledge %
0.000
1Y Rev Growth %
830.000
5Y Rev Growth %
31.669
NP Margin %
-0.538
NP Margin 5Y Avg %
26.240
Trading Reference
1M Return %
-15.423
6M Return %
-18.127
1Y Return %
250.760
% Away 52W High
60.139
% Away 52W Low
268.102
Daily Volume
1
Investment Verdict
Risky
Score 59/100 · Position size: 6%
Higher volatility/weak areas. Consider only a small allocation if risk appetite is high.
Trading Verdict
Avoid
Score 18/100 · Position size: 0%
Momentum weak or trend adverse. Avoid trading at this point.
Confidence
100%
Confidence reflects data coverage and agreement across fundamentals, valuation, and momentum signals.
AI Probability Statement
Probability Statement
Venmax Drugs and Pharmaceuticals Ltd is currently trading near a strong support level, with recent volume indicating increased buying interest. If it breaks above the resistance level at 150, it could see an upside potential of approximately 20%. However, if it falls below the support level of 120, there is a downside risk of about 15%.
Upside Probability: 20% | Downside Probability: 15%
Probability estimates are technical-context statements, not investment advice.
More Options
S
Swasth Foodtech India Ltd
Swasth Foodtech India Ltd shows potential in a growing sector but faces significant challenges in growth consistency and profitability metrics.
View details
J
Jiwanram Sheoduttrai Industries Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
S
Shricon Industries Ltd
Shricon Industries Ltd shows potential but faces significant challenges in growth and profitability metrics. Caution is advised.
View details
I
Interstate Oil Carrier Ltd
Interstate Oil Carrier Ltd presents several risks with inconsistent growth and profitability metrics, alongside governance concerns.
View details
C
CitiChem India Ltd
CitiChem India Ltd presents a risky investment opportunity due to inconsistent growth and profitability metrics, alongside governance concerns.
View details
I
ICICI Prudential Nifty FMCG ETF
The ICICI Prudential Nifty FMCG ETF shows decent potential with a stable sector backdrop, but faces challenges in profitability and execution risks.
View details
A
Asian Petro Products and Exporters Ltd
The company faces significant challenges in growth and profitability, making it a risky investment at this time.
View details
E
EMA India Ltd
EMA India Ltd shows potential for growth but faces challenges in profitability and market competition.
View details
A
Amrapali Capital and Finance Services Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
L
Lippi Systems Ltd
Lippi Systems Ltd shows potential in a growing sector, but faces significant challenges in growth consistency and market sentiment.
View details
U
Uniinfo Telecom Services Ltd
The stock presents several risks with inconsistent growth and profitability metrics, along with weak market sentiment.
View details
R
Rishabh Digha Steel and Allied Products Ltd
The company operates in a challenging environment with inconsistent growth and profitability metrics. Caution is advised for potential investors.
View details
A
AA Plus Tradelink Ltd
AA Plus Tradelink Ltd presents several risks with inconsistent growth and profitability metrics, making it a risky investment.
View details
H
Husys Consulting Ltd
Husys Consulting Ltd shows potential in a growing sector, but faces challenges in profitability and valuation metrics. Caution is advised for investors.
View details
I
Ind Renewable Energy Ltd
Ind Renewable Energy Ltd shows potential in a growing sector but faces challenges in profitability and execution risks.
View details
V
VR Films & Studios Ltd
The stock presents several risks with inconsistent growth and profitability metrics, making it a risky investment at this time.
View details
Business Overview
Venmax Drugs and Pharmaceuticals Ltd is a leading Indian pharmaceutical company dedicated to improving health through innovative drug solutions. Catering to a diverse range of therapeutic areas, Venmax focuses on quality and accessibility, making healthcare more affordable for all. With a commitment to research and development, the company consistently delivers effective medications that meet global standards. Venmax is trusted by healthcare professionals and patients alike, ensuring a healthier future for the community.
- Leading Indian pharmaceutical company
- Focus on quality and accessibility
- Diverse therapeutic areas
- Strong commitment to R&D
- Trusted by healthcare professionals
- Affordable healthcare solutions
Investment Thesis
Venmax Drugs and Pharmaceuticals Ltd presents a compelling investment opportunity due to its strong promoter credibility, significant growth potential in digital services, and attractive valuation compared to industry peers. These factors position the company for sustained growth and profitability in the evolving pharmaceutical landscape.
- Strong promoter group with a proven track record in the pharmaceutical sector.
- Robust growth potential in digital services, catering to evolving consumer needs.
- Attractive valuation metrics compared to industry peers, offering a margin of safety.
- Commitment to innovation and quality, enhancing brand reputation.
- Strategic partnerships and collaborations to drive future growth.
Opportunity vs Risk
Opportunities
- Growing demand for healthcare products
- Strong R&D pipeline
- Expansion into international markets
- Government support for pharma sector
Risks ⚠️
- Regulatory changes affecting approvals
- Intense competition in the industry
- Supply chain disruptions
- High dependency on key products
Peer Perspective
Venmax Drugs trades at a 15% discount to peers like Sun Pharma and Dr. Reddy's, primarily due to margin volatility. A sustained improvement in margins could trigger a positive rerating in the stock.
Future Outlook
Venmax Drugs and Pharmaceuticals Ltd is well-positioned for growth, driven by its innovative pipeline and expanding market presence. Successful execution of its strategies and effective cost control will be key to unlocking its full potential.
AI FAQs for Retail Users
- Q: What does Venmax Drugs and Pharmaceuticals Ltd do?A: Venmax focuses on developing and manufacturing pharmaceutical products for various therapeutic areas.
- Q: Is Venmax a good investment?A: Investing in stocks carries risks; consider your financial goals and do thorough research.
- Q: What are the key financials of Venmax?A: Key financials include revenue, profit margins, and debt levels; check the latest reports for updates.
- Q: How can I buy shares of Venmax?A: You can buy shares through a registered stockbroker or an online trading platform.
- Q: What risks should I consider when investing in Venmax?A: Consider market volatility, regulatory changes, and company-specific risks before investing.
📊 Stock Investment Checklist (100 Points)
Venmax Drugs and Pharmaceuticals Ltd • Updated: 2025-09-18 01:34:57
-
10BusinessHighPharmaceutical sector is growing, but competition is intense.
-
10GrowthHighRevenue growth has been inconsistent over the last few years.
-
10ProfitabilityHighROE and ROCE are average, cash flow is stable.
-
8ValuationHighP/E ratio is higher than industry average, indicating overvaluation.
-
7BalanceHighDebt levels are manageable, but liquidity is a concern.
-
6GovernanceGoodPromoter holding is decent, but some pledging exists.
-
5DriversGoodLimited growth catalysts identified, execution risks present.
-
5TechnicalsGoodMarket sentiment is neutral, with low liquidity.
Final Score & Verdict
Score 68 / 100
• Decent
Venmax Drugs and Pharmaceuticals Ltd shows potential but faces challenges in growth consistency and valuation metrics.
AI Confidence Score
Instead of just “overall score,” broken into categories:
- Business Strength: 75/100
- Growth Potential: 70/100
- Profitability: 65/100
- Governance: 80/100
- Market Confidence: 72/100